Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Funds / Oncology Impact Fund 2, L.P.

Oncology Impact Fund 2, L.P.

MatureUnknownFundADV: Other Private FundMPM BioimpactCayman Islands
Amounts, each with its basis
Vintage
2020basis: form d first sale
Target
unknownnot announced
First close
unknownnever inferred from a Form D
Final close
unknownonly from an announcement or an LP disclosure
Announced size
unknown
Form D offering
indefinitewhat may be sold, not what was raised; file 021-422030, sworn by the adviser or filed under this vehicle
Form D sold
$327Mas of the filing of Nov 22, 2021, 31 investors
First sale
Aug 4, 2020
Reported GAV
$826Mon the Form ADV filed Jun 26, 2024; the fund's assets, never its size or dry powder
Owners (ADV)
32
Reported on ADV
Mar 30, 2023 to Jun 26, 2024
Structure
master
Fundraising evidence
Unknown
latest Form D 2021-11-22, older than 15 months (fr-1)
evidence dated Nov 22, 2021. A Form D offering is permission to sell, not a fund in market; an amount sold is never a close; an evergreen offering amended every year is not a raise.
Lifecycle
Mature
vintage 4 to 7 years
age years: 6first sale: 2020-08-04vintage year: $2,020adv gav as of: 2024-06-26vintage basis: form_d_first_saleform d sold usd: $327Mform d offering usd: n/aform d latest filed at: 2021-11-22
The fund's own reporting through time
6 Form ADV filings
FiledTypeGross asset value OwnersMin. investmentAdviser-ownedAudit
Mar 30, 2023Other Private Fund$828M
32$5.0M1%yes
Oct 30, 2023Other Private Fund$828M
32$5.0M1%yes
Mar 28, 2024Other Private Fund$826M
32$5.0M1%yes
Jun 6, 2024Other Private Fund$826M
32$5.0M1%yes
Jun 6, 2024Other Private Fund$826M
32$5.0M1%yes
Jun 26, 2024Other Private Fund$826M
32$5.0M1%yes
Principals and agents
2 principals on Form D, 1 placement agents
  • MPM Oncology Investments 2 LLC Promoter
  • Ansbert Gadicke Executive Officer
  • UBS Financial Services Inc. placement agent
Limited partners and their reported performance
0 public LP reports
No public LP has reported this vehicle. The LP tape is read from public pension disclosures (see Limited partners); a fund appears here only when an LP’s report names it.
Investments attributed to this vehicle
0
No investment attributed to this vehicle. The firm’s investments sit on the firm; a fund gets one only when a source names the vehicle.
Timeline
2 events
  1. Mar 30, 2023
    Oncology Impact Fund 2, L.P. first reported on Form ADV by MPM Asset Management LLC (Other Private Fund), GAV $828,188,146
    Fund first reported on Form ADV Fact SEC Form ADV filing data 2011 to 2024 (every filing, Schedule D 7.B.(1) private funds, Schedules A/B)
  2. Nov 22, 2021
    Oncology Impact Fund 2, L.P. filed Form D: $326,820,000 sold (indefinite offering), Private Equity Fund
    Form D filed Fact SEC EDGAR Form D data sets (quarterly)
Evidence
16 observations
Every observation on this vehicle